Achieve Life Sciences (NASDAQ:ACHV) Stock Rating Reaffirmed by Oppenheimer

Oppenheimer reissued their outperform rating on shares of Achieve Life Sciences (NASDAQ:ACHV) in a report published on Thursday, Benzinga reports. Oppenheimer currently has a $11.00 price target on the biopharmaceutical company’s stock.

Separately, Jonestrading assumed coverage on Achieve Life Sciences in a report on Wednesday, April 17th. They issued a buy rating and a $20.00 price target for the company.

Achieve Life Sciences Price Performance

Shares of NASDAQ ACHV opened at $4.50 on Thursday. The stock has a market capitalization of $154.53 million, a price-to-earnings ratio of -3.49 and a beta of 1.54. The firm’s 50 day simple moving average is $4.75 and its 200-day simple moving average is $4.67. Achieve Life Sciences has a 12 month low of $3.03 and a 12 month high of $5.98.

Achieve Life Sciences (NASDAQ:ACHV) last released its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03). During the same quarter in the prior year, the business posted ($0.43) EPS. Analysts anticipate that Achieve Life Sciences will post -1.05 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Achieve Life Sciences

Several institutional investors have recently bought and sold shares of ACHV. Madison Park Capital Advisors LLC purchased a new position in shares of Achieve Life Sciences in the fourth quarter worth about $41,000. Virtu Financial LLC purchased a new position in Achieve Life Sciences in the 1st quarter worth approximately $59,000. The Manufacturers Life Insurance Company acquired a new position in shares of Achieve Life Sciences during the 2nd quarter worth approximately $69,000. Renaissance Technologies LLC grew its position in shares of Achieve Life Sciences by 134.2% in the second quarter. Renaissance Technologies LLC now owns 25,060 shares of the biopharmaceutical company’s stock valued at $118,000 after purchasing an additional 14,360 shares in the last quarter. Finally, Rhumbline Advisers acquired a new stake in shares of Achieve Life Sciences in the second quarter valued at approximately $197,000. 33.52% of the stock is currently owned by institutional investors and hedge funds.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.